🇺🇸 FDA
Pipeline program

Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron

J2A-MC-GZPO

Phase 3 small_molecule active

Quick answer

Orforglipron, Placebo to match LY, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron for GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials